Joshua Zeichner: October 4, 2018

NEW TREATMENT OPTION FOR THE NEARLY 10 MILLION AMERICANS SUFFERING FROM EXCESSIVE UNDERARM SWEATING

FDA APPROVES QBREXZATM (GLYCOPYRRONIUM) CLOTH TO CONTROL EXCESSIVE UNDERARM SWEATING;

RELIEVING THE BURDEN OF THIS MEDICAL CONDITION

Joshua Zeichner, MD

Zeichner Dermatology, New York City, as seen in Allure Magazine, Women’s Health

 

Primary axillary hyperhidrosis, also known as excessive underarm sweating, is a chronic medical condition that results in sweating beyond what is needed for normal body regulation.1, 2 The condition affects nearly 10 million people in the United States,3 with men and women having similar prevalence.

Did you know?

  • People with any form of hyperhidrosis generally produce 4-5 times more sweat than average to deal with heat or stress.3
  • A significant number of people report that the condition is burdensome and affects nearly all aspects of their life:
    • 85% report feeling embarrassed and 64% feel judged by others because of their hyperhidrosis.3,4
    • 61% report that hyperhidrosis influences their choice in clothing. 4
    • 75% of people say that because of the condition they find it difficult being in in public. 4
  • The exact cause of primary axillary hyperhidrosis is unknown and not attributed to another medical condition or the side effect of another medication.5

The U.S. Food and Drug Administration (FDA) has approved QBREXZA™(glycopyrronium) cloth, an anticholinergic indicated for topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older.6 QBREXZA™(glycopyrronium) cloth is applied directly to the skin and is designed to block sweat production by inhibiting sweat gland activation.6

In this satellite interview, Dr. Joshua Zeichner will talk more about hyperhidrosis – from its prevalence to symptoms – and why this condition is so impactful on one’s emotions. He’ll also talk more about what this new treatment option means for those who are affected by primary axillary hyperhidrosis.

 

For more information visit www.qbrexza.com.

 

MORE ABOUT DR. JOSHUA ZEICHNER:

Dr. Joshua Zeichner is board-certified in dermatology and the Director of Cosmetic and Clinical Research in Dermatology at the Mount Sinai Hospital in New York. He’s considered one of the country’s key opinion leaders in acne and rosacea treatments, and an expert in the use of cosmeceuticals and injectable fillers, toxins, and lasers in cosmetic dermatology. He strives to holistically treat his patients’ skin combining both medical, non-invasive in-office procedures, and proper selection of over-the-counter skin care products to customize regimens and achieve optimal results. Dr. Zeichner’s expert opinion is frequently requested by the media. He has been quoted in national magazines and newspapers, including Allure, Vogue, Elle, Glamour, InStyle, Marie Claire, Women’s Health, Cosmopolitan, Martha Stewart Living, Shape, Real Simple, Redbook, Family Circle, Dr. Oz The Good Life, and The New York Times. Dr. Zeichner has been featured on news programs including CBS News, ABC News, Pix11, The Weather Chanel, and Inside Edition. He is actively engaged in clinical research, and his work has been published in the top peer-reviewed dermatology journals. As an educator, Dr. Zeichner trains residents and medical students every day, and regularly lectures to international audiences at the major annual dermatology meetings on topics ranging from acne to cosmetic skin care. Dr. Zeichner was voted by his peers as one of New York Magazine’s Best Doctors in 2014 and is consistently ranked as one of the New York Metro Area’s Top Doctors by Castle Connolly.

 

 

 

Important Safety Information

CONTRAINDICATIONS
QBREXZA is contraindicated in patients with medical conditions that can be exacerbated by the anticholinergic effect of QBREXZA.

WARNINGS AND PRECAUTIONS
Worsening of Urinary Retention: Use with caution in patients with a history or presence of documented urinary retention.

Control of Body Temperature: In the presence of high ambient temperature, heat illness (hyperpyrexia and heat stroke due to decreased sweating) can occur with the use of anticholinergic drugs such as QBREXZA.

Operating Machinery or an Automobile: Transient blurred vision may occur with use of QBREXZA. If blurred vision occurs, the patient should discontinue use until symptoms resolve. Patients should be warned not to engage in activities that require clear vision such as operating a motor vehicle or other machinery, or performing hazardous work until the symptoms have resolved.

ADVERSE REACTIONS
The most common adverse reactions seen in ≥2% of subjects treated with QBREXZA were dry mouth (24.2%), mydriasis (6.8%), oropharyngeal pain (5.7%), headache (5.0%), urinary hesitation (3.5%), vision blurred (3.5%), nasal dryness (2.6%), dry throat (2.6%), dry eye (2.4%), dry skin (2.2%) and constipation (2.0%). Local skin reactions of erythema (17.0%), burning/stinging (14.1%) and pruritus (8.1%) were also common.

It is important for patients to understand how to correctly apply QBREXZA (see Patient Product Information). Instruct patients to wash their hands with soap and water immediately after discarding the used cloth.

Please see Full Prescribing Information.

Speak Your Mind

*